SCHEMBL24596363

SCHEMBL24596363

O=C(O)c1ccc(C(F)(F)F)nc1Nc1cccnc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.52
DHODH Q02127 8/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 2/20 0.45
HIF1A Q16665 2/20 0.45
GMNN O75496 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TTR P02766 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
PKM P14618 1/20 0.45
NFKB1 P19838 1/20 0.45
UGT1A1 P22309 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
PMP22 Q01453 1/20 0.45
TEAD4 Q15561 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596345 0.88 DHODH (0.56) TAS2R14DHODHHDAC6MEN1KMT2A
SCHEMBL24596362 0.86 TAS2R14 (0.44) TAS2R14DHODHHDAC6KMT2ALMNA
SCHEMBL24596367 0.83 DHODH (0.47) TAS2R14DHODHHDAC6MEN1KMT2A
SCHEMBL29789888 0.81 TAS2R14 (0.52) TAS2R14DHODHHDAC6MEN1KMT2A
SCHEMBL24596386 0.81 TAS2R14 (0.52) TAS2R14DHODHHDAC6MEN1KMT2A
SCHEMBL24596343 0.79 SYK (0.37) TAS2R14DHODHHDAC6MEN1KMT2A
SCHEMBL30721208 0.78 DHODH (0.53) TAS2R14DHODHMEN1KMT2ALMNA
SCHEMBL12984259 0.78 DHODH (0.53) TAS2R14DHODHMEN1KMT2ALMNA
SCHEMBL26631681 0.78 TAS2R14 (0.49) TAS2R14DHODHHDAC6LMNASYK
SCHEMBL30611256 0.77 DHODH (0.48) TAS2R14DHODHMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A TAS2R14 3543/4885DHODH 3731/4885HDAC6 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.